58
Participants
Start Date
April 30, 2007
Primary Completion Date
July 31, 2010
Study Completion Date
December 31, 2011
Extended Release Tolterodine LA
Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks
Intra Vaginal Estradiol Cream
17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
Collaborators (1)
Pfizer
INDUSTRY
University of Alabama at Birmingham
OTHER